Ethinylestradiol/levonorgestrel transdermal - Agile Therapeutics

Drug Profile

Ethinylestradiol/levonorgestrel transdermal - Agile Therapeutics

Alternative Names: AG 200 ER; AG 200 SP; AG-200-15; Ethinyl estradiol and levonorgestrel transdermal system; Low dose EE/LNG; Twirla

Latest Information Update: 19 Jan 2017

Price : $50

At a glance

  • Originator Agile Therapeutics
  • Class Alkylated estrogenic steroids; Contraceptives; Hormonal replacements; Norpregnanes; Norpregnatrienes; Small molecules
  • Mechanism of Action Estrogen receptor agonists; Progesterone receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preregistration Contraception

Most Recent Events

  • 03 Jan 2017 Top-line adverse events data from the phase III SECURE trial in Contraception released by Agile Therapeutics
  • 03 Jan 2017 Agile Therapeutics completes the phase III SECURE trial for Contraception in USA
  • 07 Nov 2016 Agile Therapeutics announces intention to re-submit NDA to US FDA in the first half of 2017
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top